Compare FBP & STVN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | FBP | STVN |
|---|---|---|
| Founded | 1948 | 1949 |
| Country | United States | Italy |
| Employees | N/A | N/A |
| Industry | Major Banks | Containers/Packaging |
| Sector | Finance | Consumer Discretionary |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.6B | 3.7B |
| IPO Year | 2010 | 2021 |
| Metric | FBP | STVN |
|---|---|---|
| Price | $23.31 | $16.09 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 5 | 3 |
| Target Price | $25.20 | ★ $25.67 |
| AVG Volume (30 Days) | ★ 1.4M | 629.9K |
| Earning Date | 04-22-2026 | 05-07-2026 |
| Dividend Yield | ★ 3.29% | 0.39% |
| EPS Growth | ★ 18.78 | N/A |
| EPS | ★ 2.15 | N/A |
| Revenue | ★ $1,255,034,000.00 | N/A |
| Revenue This Year | $15.10 | $9.67 |
| Revenue Next Year | $4.65 | $9.99 |
| P/E Ratio | ★ $11.30 | $27.15 |
| Revenue Growth | ★ 2.38 | N/A |
| 52 Week Low | $19.16 | $12.89 |
| 52 Week High | $24.35 | $28.00 |
| Indicator | FBP | STVN |
|---|---|---|
| Relative Strength Index (RSI) | 58.32 | 63.37 |
| Support Level | $19.54 | $13.58 |
| Resistance Level | N/A | $16.69 |
| Average True Range (ATR) | 0.54 | 0.75 |
| MACD | 0.11 | 0.29 |
| Stochastic Oscillator | 60.26 | 69.28 |
First BanCorp is a financial holding company. The company's operating segment includes Commercial and Corporate Banking; Mortgage Banking; Consumer (Retail) Banking; Treasury and Investments; United States Operations; and Virgin Islands Operations. It generates maximum revenue from the Consumer (Retail) Banking segment. The Consumer (Retail) Banking segment generates majority revenue, which consists of the Corporation's consumer lending and deposit-taking activities conducted mainly through its branch network and loan centres. Geographically, it derives a majority of revenue from Puerto Rico.
Stevanato Group SpA is a provider of drug containment, drug delivery and diagnostic solutions to the pharmaceutical, biotechnology and life sciences industries. It delivers an integrated, end-to-end portfolio of products, processes, and services that address customer needs across the entire drug life cycle including development, clinical, and commercial stages. It has two segments; Biopharmaceutical and Diagnostic Solutions which generates key revenue, includes all the products, processes and services developed and provided for the containment and delivery of pharmaceutical and biotechnology drugs and reagents, as well as the production of diagnostic consumables and its other segment is Engineering. Geographically, It derives its majority revenue from Europe, Middle East and Africa.